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Abstract
Background: Comprehensive characterization of the phosphoproteome in living cells is critical in signal
transduction research. But the low abundance of phosphopeptides among the total proteome in cells remains an
obstacle in mass spectrometry-based proteomic analysis. To provide a solution, an alternative analytic strategy to
confidently identify phosphorylated peptides by using the alkaline phosphatase (AP) treatment combined with
high-resolution mass spectrometry was provided. While the process is applicable, the key integration along the
pipeline was mostly done by tedious manual work.
Results: We developed a software toolkit, iPhos, to facilitate and streamline the work-flow of AP-assisted
phosphoproteome characterization. The iPhos tookit includes one assister and three modules. The iPhos Peak
Extraction Assister automates the batch mode peak extraction for multiple liquid chromatography mass
spectrometry (LC-MS) runs. iPhos Module-1 can process the peak lists extracted from the LC-MS analyses derived
from the original and dephosphorylated samples to mine out potential phosphorylated peptide signals based on
mass shift caused by the loss of some multiples of phosphate groups. And iPhos Module-2 provides customized
inclusion lists with peak retention time windows for subsequent targeted LC-MS/MS experiments. Finally, iPhos
Module-3 facilitates to link the peptide identifications from protein search engines to the quantification results
from pattern-based label-free quantification tools. We further demonstrated the utility of the iPhos toolkit on the
data of human metastatic lung cancer cells (CL1-5).
Conclusions: In the comparison study of the control group of CL1-5 cell lysates and the treatment group of
dasatinib-treated CL1-5 cell lysates, we demonstrated the applicability of the iPhos toolkit and reported the
experimental results based on the iPhos-facilitated phosphoproteome investigation. And further, we also compared
the strategy with pure DDA-based LC-MS/MS phosphoproteome investigation. The results of iPhos-facilitated
targeted LC-MS/MS analysis convey more thorough and confident phosphopeptide identification than the results
of pure DDA-based analysis.
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Background
Phosphorylation is a crucial protein post-translational
modification (PTM) in many biological processes [1].
And many human diseases, such as cancer and the Alz-
heimer’s disease, are discovered to be triggered by the
dysregulation of phosphorylation and dephosphorylation
[2,3]. In eukaryotes, protein kinases catalyze the addition
of phosphate groups to the side chains of hydroxyl-con-
taining amino acids (serine, threonine and tyrosine)
[2,3]. In particular, over 45 protein tyrosine kinases have
been implicated in the pathogenesis of human cancers
[4]. And nowadays tyrosine-phosphorylated (pTyr) pro-
teins are specific targets for the development of poten-
tial biomarkers in prognosis, diagnosis and prediction of
drug responses [5]. But the low stoichiometry of phos-
phorylated proteins is still a significant challenge for
identifying them [6].
In the past, protein phosphorylation is detected by
antibodies recognizing specific phosphorylated epitopes
and/or by the use of 32P labelled gATP to incorporate
labelled phosphorylation into proteins. These labour-
intensive procedures are prone to false phosphorylation
site assignment and hence are not suitable for compre-
hensive analysis [7]. With the development of liquid
chromatography mass spectrometry (LC-MS) technology
coupled with refined protein enrichment methods, such
as immobilized metal affinity chromatography with Fe
(III) or Ga(III) [8,9], metal oxide affinity chromatogra-
phy with TiO2 or ZrO2 [10,11] or phosphoramidate
chemistry [12], it is becoming more and more available
for large scale phosphoproteome investigation [13,14].
For many years, collision induced dissociation (CID) is
the major core method for tandem MS scan of peptides
and proteins with/without PTMs. Other fragmentation
methods such as electron transfer dissociation (ETC)
were also proposed to identify phosphorylated proteins
but are generally not efficient to be used in the analysis
of lowly-abundant pTyr peptides [15]. When undergoing
CID, neutral loss of 98 Da (H3PO4) for peptides with
phosphorylated-serine (pSer) and phosphorylated-threo-
nine (pThr) would occur and impede the identification
of these peptides in data dependent MS/MS [16].
Instead, neutral loss scan, such as MS3 and MultiStage
Activation, that imposes additional activation events on
the neutral loss peaks can be utilized to detect pSer and
pThr peptides [17,18]. But tyrosine phosphorylation is
largely exempt from the b-eliminated neutral loss of 98
Da and are not suitable for these type of neutral loss
scan analysis [16]. The identification of pTyr proteins
are mainly through the data-dependent acquisition
(DDA)-based LC-MS/MS, which adopts some user-
defined criteria to serially select the top intense ions in
a survey MS scan of all precursor ions for subsequent
CID fragmentation and generates the corresponding
product ion spectra for protein database searching or
manual interpretation. An alternative for detecting tyro-
sine phosphorylated peptides is to detect selectively the
signal at m/z of 216.043 (the immonium ion) [16,19,20].
Though the neutral loss scan experiments, pure DDA-
analysis and selective detection of immoniun ion work
well in semi-complex mixtures, in real complex samples
such as cell lysates these types of analysis tend to fail to
identify most of the phosphopeptides due to the low
abundance of phosphorylated peptides and the suppres-
sion effect in the presence of those non-phosphorylated
peptides [21,22].
To overcome this obstacle, there is a proposed alter-
native in which biologist combine the alkaline phospha-
tase (AP) treatment to facilitate a reference-based signal
data mining for phosphoproteome analysis [23]. In this
additional AP treatment after standard phosphopeptide
enrichment procedures such as TiO2 microcolumns,
researchers further focused on the signals with mass
shift of some multiples of 79.966 Da (PO3
3-) detected by
comparing the phosphopeptide signals and the corre-
sponding dephosphorylated peptide signals. This has
been shown to provide more confident and comprehen-
sive phosphoproteome investigation with lower false
positive rate [7,24-26]. And this AP-treatment alterna-
tive approach targeting on those signals with mass shift
are also shown to provide better discrimination of pTyr
peptides in the lung cancer cell lysates [27]. While the
overall process, including tyrosine-specific antibody
treatment, AP treatment, mass shift calculation and
label-free quantification, is applicable, the key integra-
tion along the pipeline was mostly done by tedious
manual work or private in-house software. To promote
and facilitate this comprehensive data mining-based
phosphoproteome investigation, developing the fully
facilitating toolkit is urgent.
To facilitate the overall workflow of the AP-assisted
comprehensive phosphoproteome investigation, we devel-
oped the software package, iPhos. iPhos is a collection of
signal data mining and analysis facilitating tools to stream-
line the workflow for routine phosphoproteome character-
ization. The iPhos toolkit includes one assister and three
modules. iPhos Module-1 is used for signal processing of
the LC-MS signal peaks extracted by peak extraction com-
putational tools to mine out signals with mass shift
between the original and dephosphorylated samples. In
addition to iPhos Module-1, we further design the iPhos
Peak Extraction Assister to help users automate the batch
mode msInspect-based peak extraction procedure [28].
iPhos Module-2 provides customized m/z inclusion lists
with peak retention time windows for subsequent targeted
LC-MS/MS experiments. iPhos Module-3 is designed to
aid the pattern-based label-free quantification. Since most
of the pattern-based label-free tools did not link the
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information of peptide identification to the quantification
results [29], we developed iPhos Module-3 to connect spe-
cific phosphopeptide identifications with quantification
results generated by pattern-based label-free quantification
tools. In addition, iPhos Module-3 can help researchers fil-
ter out those peptides with proper phosphorylation site
assignment. The iPhos toolkit aims to facilitate the AP-
assisted and data mining-based comprehensive phosphos-
proteome investigation and quantification. The utility of
the iPhos toolkit was evaluated through the analysis of the
differential expression levels of pTyr proteins between
metastatic lung cancer cells with tyrosine kinase inhibitor-
treatment and cells without treatment. We reported the
results of the tyrosine phosphosproteome investigation
facilitated by iPhos and showed the improved pTyr pep-
tide identification over the results generated by the
method of pure DDA LC-MS/MS phosphoproteome ana-
lysis. The iPhos toolkit is available online at http://cosbi3.
ee.ncku.edu.tw/iPhos/.
Implementation
The developed iPhos software toolkit was written in
Python 2.6 and the web service was built using the PHP
CodeIgniter framework. The overall experiment work-
flow of conducting comparison studies based on the
AP-assisted phosphoproteome investigation was pro-
posed by various researchers [22-24,26] and was sum-
marized by Wu et al. [27] (Figure 1). We developed the
key integrative tools, collectively called iPhos, to facili-
tate the workflow. These key integrative tools are
described as follows.
Raw data conversion
The raw files for the AP-treated and untreated samples
generated by mass spectrometers should first be con-
verted into the open file representation format of
mzXML, which is now a routine job for analysing MS
data. It can be done by suitable programs developed by
the Seattle Proteome Centre (SPC) [30]. For example,
the ReAdW program can be used for raw files from the
LTQ-Orbitrap Velos hybrid mass spectrometers. Or
users can use the recently updated tool MSConvert pro-
vided in the ProteoWizard project [31], by which a GUI
interface was constructed for Microsoft Windows users.
iPhos peak extraction assister (iPhos PEA)
To perform the signal data mining for extracting phos-
phopeptide signal, we need first to extract the peak sig-
nals from the raw experimental LC-MS data. LC-MS
data provides 2-dimensional aspect of the proteome
under investigation in retention time and m/z values and
the signals forming peaks in this 2-dimensional map
represents the potential peptide signals [28,32]. Various
algorithms and tools, such as VIPER [33], SuperHirn
[34], Peplist [35], OpenMS [36], ICPD [32], and msIn-
spect [28], have been developed to extract the peak sig-
nals. In our previous works, we have demonstrated the
use of msInspect in the phosphoproteome investigation
[27]. Therefore in the development of the iPhos toolkit,
we choose msInspect as the default tool for peak extrac-
tion, but users are still freely to select any peak extraction
software to generate the peak lists. msInspect acquires
peak information after peak detection, monoisotopic
peak determination and the calculation of original
masses. But msInspect requires the user to allocate
proper system memory for the java-based application.
Further, batch mode for peak extraction is not possible.
Hence in the iPhos toolkit, we developed a peak extrac-
tion assister that automate the memory allocation and
batch mode peak extraction using the default peak
extraction tool msInspect. In this peak extraction assister,
users can specify the directory where the mzXML files
are located and the peak extraction will be automatically
completed by the assister (Figure 1-a).
iPhos Module-1: phosphopeptide signal extraction
iPhos module-1 uses the extracted peak information to
find the potential phosphopeptide signals according to
mass shift of some multiples of -79.966 Da upon depho-
sphorylation introduced by the AP treatment (Figure 1-b).
Users are freely to select any peak extraction software as
long as they provide the header information of the peak
list files that is to be used in iPhos Module-1. Up to six
pairs of replicas with and without AP treatment, respec-
tively, can be processed by iPhos Module-1. To avoid the
inclusion of noise peak signals, users can set the appropri-
ate cut-off values on the extracted peaks. The intensity
threshold can be decided with the aid of the visual charts
generated in this module. The cut-off value N can be
determined using the greatest slope change in the output
chart to select only the top N peaks of phosphorylated and
dephosphorylated peptides. Finally, users should specify
the mass tolerance and retention time window used for
signal mass shift mining. In addition, users can also cus-
tom the quantity of the mass shift, making iPhos vulner-
able to the investigation of other PTMs.
iPhos Module-2: inclusion list generation for targeted LS-
MS/MS
iPhos module-2 was designed so that users can customize
the m/z inclusion lists for the downstream targeted LC-
MS/MS analysis (Figure 1-c). By setting the user-defined
parameters on peptide elution times, users can generate
equally-divided inclusion list segments of phosphopeptide
candidates with their retention time windows that best suit
the downstream MS/MS spectrometer [27]. With the limits
of mass spectrometers, duplicated m/z values resulted from
different biological replicas will be eliminated based on the
Yang et al. BMC Bioinformatics 2014, 15(Suppl 16):S10
http://www.biomedcentral.com/bmcbioinformatics/supplements/15/S16/S10
Page 3 of 14
Figure 1 Overall workflow for the iPhos-facilitated comprehensive phosphoproteome investigation. This figure is the sketch plot of the
overall iPhos-facilitated phosphorylated peptide identification and quantification work-flow. The input and output file formats for different
modules are shown in grey. The key integrative tools, collectively called iPhos, to facilitate the workflow are highlighted in (a)-(d). (a) iPhos Peak
Extraction Assister automates the msInspect-based batch mode peak extraction. (b) iPhos Module-1 processes the LC-MS data for
phosphopeptide signal extraction. (c) iPhos Module-2 generates customized inclusion lists for subsequent targeted LS-MS/MS analysis. (d) iPhos
Module-3 links the results of phosphopeptide identification with pattern-based label-free quantitative analysis.
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round off decimals of m/z values. For comparative experi-
ments, iPhos module-2 can combine signals with mass
shifts from samples obtained from different conditions [27].
iPhos Module-3: integration of phosphopeptide
identification and pattern-based label-free quantitative
analysis
Since the level of phosphorylation of a protein may be
crucial for its function, quantitative information for
phosphopeptides is required in the phosphoproteome
investigation [17]. While traditional quantification of
phosphopreteome is based on labelling methods such as
SILAC or iTRAQ [16], the cost-efficient method of label
free-quantification method is now a catching-on alterna-
tive [26,27,29]. Label-free method can be categorized
into three different types [29]. The first type is identifi-
cation-based quantification using spectral counts. This
type of is generally not suitable for phosphoproteome
quantification because the identification of phosphoryla-
tion is based on only single or few peptide identification
[18,24]. The second type is pattern-based quantification
using peak identification and XIC calculation. The third
type is hybrid-based quantification using the peptide
identification as the starting point to calculate the corre-
sponding XIC area. Among these popular quantification
methods, the use of SILAC labelling quantification and
the pattern-based label-free quantification rely on only
MS information. Most of the commercial and open
source LC-MS quantification tools based on these two
do not link the peptide identification information with
the quantification results, thus lacking the phosphoryla-
tion site localization.
To facilitate the phosphorylation site localization for
quantification tools based on SILAC labelling or pattern-
based label-free methods, iPhos Module-3 was designed to
integrate the peptide identification from the targeted LC-
MS/MS analysis with the quantification results of LC-MS
experiments (Figure 1-d). The LC-MS quantification can
be done by pattern-based label-free quantification software
tools such as msInspect [28] and mzMine [37], which first
extract all peaks from each MS data and then align them
across different runs [38]. Users are required to input the
header information of the quantification results that is to
be used in iPhos Module-3. Peptide identification should
be the search results by major database search engines
such as Mascot. In iPhos Module-3, the properties of
peaks, such as m/z, retention time and charge state, are
utilized to link the phosphopeptide identification from the
targeted LC-MS/MS analyses with the quantification
results of the corresponding LC-MS comparative experi-
ments. In addition, in iPhos Module-3 users can specify
the phosphorylation type (pSer, pThr, pTyr) in concern to
further filter out the intended phosphorylated peptides.
iPhos Module-3 can also facilitate the integration of
DDA LC-MS/MS peptide quantification and peptide iden-
tification in a similar manner (Figure 2). Moreover, iPhos
Module-3 can be extended to support for the catching-on
data independent acquisition (DIA) LC-MS methods (Fig-
ure 3). In the LC-MS DIA experiment settings, the peptide
quantitative information can be acquired for each precur-
sor ion during the low energy scan cycle using standard
pattern-based quantification tools [39]. For peptide identi-
fication, the composite spectra of MSE data obtained in
the elevated energy scan cycle can be analysed with the
standard database search tools (such as Mascot) developed
for DDA analysis [40], either by directly searching the
composite spectra [41] or by searching the reconstructed
pseudo-MS/MS DDA spectra [42-45]. This can be done
by software products such as ProteinLynx Global SERVER
(PLGS), DeMux [42], ETISEQ [45] and other similar tools.
To facilitate the DIA phosphopeptide identification, iPhos
Module-3 connects the peptide identification results from
any of these database search methods with the standard
MS peptide quantification results from pattern-based
quantification software. And iPhos Module-3 further helps
extract those phosphopeptides of interest with Mascot
scores above the user-defined threshold.
Demonstration dataset
Cell lysate preparation
The human lung adenocarcinoma cells CL1-5 cells
selected by the in-vitro invasion assay were kindly pro-
vided by Dr. Pan-Chyr Yang (Academia Sinica, Taipei,
Taiwan) and cultured in the RPMI-1640 medium
(Gibco, Gaithersburg, MD) supplemented with 10%
fetal bovine serum (Gibco), penicillin and streptomycin
(Thermo Scientific, Logan, Utah). Cells were incubated
at 37°C containing 5% CO2. Dasatinib (Santa Cruz Bio-
technology, Santa Cruz, CA) was prepared at 0.1 mM
in a DMSO vehicle (Sigma-Aldrich, St. Louis, MO).
When achieving 70-80% confluence, parts of the cells
were treated with a final concentration of 0.1 μM dasa-
tinib in a 0.1% DMSO vehicle for 48 hours. The con-
trol and dasatinib-treated CL1-5 cells were centrifuged
at 800 × g for 10 min. Both cell pellets were suspended
in PBS buffer and subsequently lysed by 2 ml lysis buf-
fer (50 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 0.5%
sodium deoxycholate, 0.1% SDS, 1 × protease inhibitor
cocktail (Roche Applied Science, Indianapolis, IN), and
phosphatase inhibitor mixture (2 mM sodium orthova-
nadate, 5 mM sodium fluoride, and 10 b-glycerolpho-
sphate)). After centrifuged at 12,000 × g for one hour,
the supernatant was collected. Some of the supernatant
was then extracted for protein concentration estima-
tion by using a bicinchoninic acid (BCA) protein assay
(Pierce, Rockford, IL).
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Immunoprecipitation and in-gel digestion
1.4 mg of proteins were resuspended in 600 μl of lysis
buffer and then reacted with 100 μl of agarose-immobi-
lized pTyr-specific antibody 4G10 (Millipore, Temecula,
CA) and PT66 (Sigma-Aldrich). After the antibody
treatment, samples were washed three times with 1 ml
radioimmunoprecipitation assay (RIPA) buffer and
eluted using 80 μl 4× sample buffer (Invitrogen, La Jolla,
CA) supplemented with 400 mM dithiothreitol (DTT).
To concentrate the eluted proteins, SDS-PAGE com-
posed of a 5% acrylamide stacking gel and a 20% acryla-
mide separating gel was used. After electrophoresis at
50 V for 30 min, the gel was then stained with Coomas-
sie blue for one hour. The protein band was passed
through a destaining solution (H2O/methanol/acetic
acid in a ratio of 50/40/10 (v/v/v)) and excised in pieces
of 1 mm3, which were then subjected to in-gel digestion.
The destained gel pieces were washed twice with solu-
tion of 50% (v/v) acetonitrile (ACN) / 25 mM ammo-
nium bicarbonate. The spots were reduced with 10 mM
DTT for one hour at 56°C and alkylated with 55 mM
iodoacetamide for 45 min in the dark at room tempera-
ture. Subsequent digestion was performed by incubating
the samples with 0.1 μg of TPCK-treated modified por-
cine trypsin (Promega, Madison, WI) at 37°C overnight.
The extracts of the pieces were prepared using 20 μl of
50% CAN / 5% formic acid; these extracts were com-
bined with the supernatant containing the tryptic pep-
tides. The samples were then dried using a centrifugal
evaporation instrument (Vacufuge, Eppendorf, Hamburg,
Germany).
Phosphopeptide enrichment by TiO2 pipette tips and AP
treatment
The tryptic peptides were suspended with 100 μl solu-
tion A (0.1% Trifluoroacetic acid (TFA), 80% ACN with
300 mg/ml lactic acid) and loaded onto the TiO2 pipette
tip (200 μ l/3 mg, GL science, Torrance, CA) for phos-
phopeptide binding. After centrifuge, we repeated the
binding step twice. The wash step was performed with
solution A and solution B (0.1% TFA, 80% ACN) suc-
cessively. Then 50 μl 0.5% ammonium hydroxide was
added to the tips for elution. A quarter of the eluted
samples were further treated with alkaline phosphatase
(AP). This quarter of the samples for AP treatment was
adjusted with dephosphorylation buffer (Roche) to pH
8-9 and then incubated with 1 U of AP (Roche) at 37°C
Figure 2 The experimental settings in this work. The experimental procedures used in the comparative analysis of the control CL1-5 cells
and the dasatinib-treated CL1-5 cells. Beside the analytical strategy of AP-assisted phosphoproteome investigation, we further performed the
commonly used strategy of pure DDA LC-MS/MS analysis. For confidence comparison, we assessed the results of the AP-assisted targeted
LC-MS/MS and the results of pure DDA LC-MS/MS analysis.
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for 2 h. After that, 2.5% TFA were added to all the
eluted samples and the samples were desalted by C18
pipet tips (Varian, Lake Forest, CA). The eluate was eva-
porated and suspended with 10 μl of 5% ACN in 0.1%
TFA solution before nanoLC-MS analysis. For generat-
ing the targeted phosphopeptide signals in this study,
we categorized four experimental groups: CL1-5, CL1-5
with AP treatment, dasatinib-treated CL1-5, and dasati-
nib-treated CL1-5 with AP treatment.
NanoLC-MS analysis
The samples were analysed by full-scan LC-MS on a
nano-ACQUITY system (Waters, Milford, MA) coupled
with an LTQ-Orbitrap Velos hybrid mass spectrometer
(Thermo Scientific) which is equipped with a PicoView
nanospray interface (New Objective). Peptide mixtures
were loaded onto a 75-μm × 250-mm nano-ACQUITY
UPLC BEH130 column packed with C18 resin (Waters)
and were separated at a flow rate of 300 nl/min using a
linear gradient of 5% to 40% solvent B (95% acetonitrile
with 0.1% formic acid) for 60 min, followed by a sharp
increase to 85% solvent B at 1 min and then a holding
period at 85% solvent B for another 10 min. Solvent A
was 0.1% formic acid in water. The effluent from the
HPLC column was directly electrosprayed into the mass
spectrometer. The LTQ-Orbitrap Velos instrument was
operated in full scan MS acquisition mode. Full scan
MS spectra (m/z 300-2000) were acquired in the Orbitrap
analyser with resolution set at 60,000 (all Orbitrap system
resolution values are given at m/z 400). The standard
mass spectrometric conditions for all experiments were as
the following: spray voltage, 1.8 kV; no sheath and auxili-
ary gas flow; heated capillary temperature, 200 °C; predic-
tive automatic gain control (AGC) enabled; and an S-lens
RF level of 50%. The instrument was controlled by Tune
2.6.0 and Xcalibur 2.1 software.
Targeted LC-MS/MS analysis and database search
The m/z values with retention time windows of possible
pTyr peptide signals were obtained from iPhos Module-
2. We further divided the remaining half of the samples
into two portions. The inclusion lists on the same LTQ-
Orbitrap Velos hybrid mass spectrometer triggered MS/
MS analysis once these m/z values were captured on
one portion of the pooled control and treated samples.
The other portion was subjected to data-dependent
acquisition (DDA) as a comparison with the targeted
LC-MS/MS analysis. Each scan of the mass spectro-
meter contained one full scan mass spectrum (m/z
300-2000) followed by 20 tandem mass spectra with the
collision energy set at 35%. The targeted LC-MS/MS
mode was devised that ten most intense ions from the
inclusion list were used for LC-MS/MS analysis. In the
targeted MS/MS mode, if there was no signal matching
the inclusion list in full scan, the DDA mode was used.
The method of multi-stage activation was applied and
the neutral losses were set as 97.98, 79.97, 48.99, 39.98,
32.66, and 26.66.
All MS raw data were processed by Raw2MSM and
searched against the IPI human database (Version 3.87)
using an in-house Mascot server (Version 2.2, Matrix
Science Ltd., London, UK) with a confidence level of 95%.
Up to two missed cleavages were allowed for the trypsin
digestion simulation. We allowed the variable modifica-
tions of Carboxyamidomethylation on Cys, deamidation
on Asp and Glu, oxidation on Met, and phosphorylation
on Ser, Thr, and Tyr. Mass deviations for precursor ions
and fragment ions were all set to 1 Da. A false discovery
Figure 3 Extended support for DIA LC-MS methods. iPhos
Module-3 can be extended to support both the DDA
phosphoproteome analysis and the DIA phosphoproteome analysis
by facilitating the integration of the phosphopeptide quantification
results with pattern-based label-free quantification software with the
phosphopeptide identification results from the major protein
database search engines.
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rate of ≤ 5% was set based on the calculation by the Mas-
cot-integrated decoy database search.
Results and discussion
CL1-5 cell lysate phosphoproteome investigation assisted
by iPhos
To demonstrate the utility of the iPhos toolkit in a
large-scale quantitative tyrosine phosphoproteomics
study, two enriched pTyr protein mixtures were pre-
pared from the control and dasatinib-treated CL1-5
cells. It has been shown that several pTyr proteins
involved in Src kinase regulation have different expres-
sion levels in the human metastatic lung cancer cell line
CL1-5 compared with the less invasive sub-population
of CL1-0 [27]. And dasatinib is an anti-tumour drug
that inhibits Src family tyrosine kinases and is frequently
used to evaluate changes in pTyr protein expression
levels before and after treatment [46,47]. pTyr proteins
were immunoprecipitated using a combination of two
pTyr specific antibodies, 4G10 and PT66. To form a
comparison study, we use the CL1-5 cells as the control
group and dasatinib-treated CL1-5 cells as the treatment
group. Half of both samples were further divided into
two portions and one of this sub-portion was treated
with alkaline phosphatase. The other half of both sam-
ples was also divided into two portions: one portion
used for targeted LC-MS/MS analysis and the other por-
tion used for DDA LC-MS/MS analysis. We scattered
each part into three technical replicas to measure repro-
ducibility. The overall datasets and settings of the com-
parison study are shown in Figure 2.
We set the following parameters in iPhos Module-1:
top 3000 peaks cut-off value in phosphorylated and
dephosphorylated runs; 79.966 Da mass shift; 0.05 Da
mass tolerance; 5 min peak retention time shift toler-
ance; up to 5 phosphate groups modified; charge state
at least 2. Then we loaded the potential phosphopeptide
signals mined out from both the control and treatment
group by iPhos Module-1 into iPhos Module-2. In iPhos
Module-2, we set the time range to be 10 to 60 min
according to the exact peak elution time in the gradient
of solvent B and generated the inclusion lists by separat-
ing these potential pTyr peptides signals into 10 seg-
ments with 1.5 min extra retention time tolerance in
each segment. The round-off decimal was set to be 2.
Overall, 262 unique signals with specific retention time
window was found and input as the “inclusion list” in
the LTQ-Orbitrap Velos mass spectrometer for targeted
LC-MS/MS analysis. These 262 signals were extracted
from about 19,000 monoisotopic peaks presented in all
LC-MS runs, including the original samples and the
dephosphorylated samples (Figure 4).
Then we used iPhos module-3 to combine the quanti-
fication results from Progenesis (Nonlinear Dynamics,
Newcastle upon Tyne, UK) and the pTyr peptide identifi-
cation results from the Mascot search engine. The para-
meters used in iPhos Module-3 was set as the following:
Mascot score higher than 25; 0.2 Da m/z tolerance; 2 min
retention time tolerance; pTyr peptide modification.
Beside the spiked-in internal standard peptides
(MSYNCCSGNFSSR), a total of 125 pTyr peptides are
identified and quantifiable in the control and treatment
group (See Additional File 1). And there are 18 differen-
tially expressed pTyr peptides (using the ANOVA test
with a = 0.05, shown in Table 1).
Demonstration example of AP-assisted phosphopeptide
identification
The central dogma of the iPhos-facilitated phosphopro-
teome investigation is based on the loss of phosphate
group(s) (-79.966n Da) to extract potential phosphopep-
tide signals as the inclusion lists for targeted LC-MS/MS
analysis. We take a demonstration example from our data-
sets to show the idea. The partial sequence (DEHLSTL-
DApYRPK) of the protein named “Similar to ankyrin
repeat domain 20A, isoform CRA_a” was identified in all
targeted LC-MS/MS runs. After signal data mining of
iPhos Module-1 and Module-2, the original peptide mass
of 1623.701 Da (from m/z 812.858, 2+) in the AP-
untreated run compared with 1543.725 Da (from 772.870,
2+) in the AP-treated run reveals a mass shift of -79.9767
Da (HPO3) (Figure 5-a). The m/z of 812.8579 was rounded
to 812.86 and set as the potential peak signal in the inclu-
sion list with retention time window from 21.51 to 28.43
min. After the targeted LC-MS/MS scan, the pTyr peptide
sequence of DEHLSTLDApYRPK was identified and
reported by the Mascot search engine with a score of
39 and eluted in the time range of 23.32 to 27.25 min. The
MS/MS spectrum of this peptide signal is shown in Figure
5-b. Notice that the elution time found by the MS/MS
analysis coincided with the retention time window
provided by iPhos Module-2.
Improvement over DDA-based phosphoproteome
investigation
iPhos-facilitated investigation obtains more pTyr peptide
identification and reproducibility
We have divided our samples to separately perform the
iPhos-facilitated target LC-MS/MS analysis and DDA LC-
MS/MS analysis for comparison. These two sub-portions
are identically prepared but are subject to different LC-
MS/MS analysis. We manually collected the identified
pTyr peptides in these two analyses. There are 308 and
255 pTyr peptides identified by the Mascot search engine
(score ≥ 25) in the targeted LC-MS/MS analysis and DDA
LC-MS/MS runs, receptively. A 20.1% improvement on
the number of identified pTyr peptides was obtained from
the iPhos-facilitated phosphoproteome investigation. Of
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Figure 4 Illustration of phosphopeptide signal data mining. Three-dimensional (retention time, m/z and signal intensity) representation of
the LC-MS signals before and after the signal data mining of iPhos Module-1. (a) Approximately 19,000 monoisotopic signals are in the tryptic
pTyr-enriched protein mixture samples that were not alkaline phosphatase treated. (b) The signals in the tryptic pTyr-enriched protein mixture
that has undergone alkaline phosphatase dephosphorylation. (c) iPhos Module-1 extracted 262 possible pTyr signals with mass shifts of some
multiples of phosphate group loss.
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these identified pTyr peptides, 117 pTyr peptides identi-
fied in the targeted LC-MS/MS analysis were found in
more than one technical replicas and showed reproducibil-
ity. In comparison, only 66 pTyr peptides identified in the
DDA LC-MS/MS analysis embraced reproducibility.
These results are in agreement with observations in other
recent studies [48-50].
Confidence evaluation
Owing to the presence of multiple potential phosphoryla-
tion sites in a peptide, the common scoring system in
peptide search engines such as Mascot and Sequest do
not properly evaluate phosphorylation site assignment
[51-53]. Two solutions were proposed. One is to use the
Mascot Delta Score (MD-score) for proper evaluation of
the phosphorylation site localization [53]. The MD-score
method calculates the difference between the top two
Mascot ion scores of alternative phosphorylation sites for
the identical peptide sequence from Mascot search
results. The other evaluation metric is provided by Phos-
phoRS, a tool to automate confident localization of phos-
phorylation sites [54]. PhosphoRS provides the individual
probability values for each putative phosphorylated site
based on the given MS/MS data. We used both the MD-
score and PhosphoRS (Proteome Discoverer: version 1.3,
Thermo. Scientific) to compare the confidence of the
uniquely identified pTyr peptides from the targeted
LC-MS/MS analysis and the DDA LC-MS/MS analysis.
As shown in Figure 6-a, the MD-scores of the identi-
fied pTyr peptides are higher in the targeted LC-MS/MS
analysis (19.24 ± 0.19) than the MD-scores in DDA LC-
MS/MS analysis (17.55 ± 0.68). And it is reported that
the MD-score should be more than 5 so as to unam-
biguously determine phosphorylation sites [55,56]. In
our experimental results, only 15.18% (29/191) of the
MD-scores in targeted LC-MS/MS analysis are less than
5. In contrast, 24.86% (47/189) of the MD-score in DDA
LC-MS/MS analysis does not reach above the threshold
of 5. From the evaluation of the MD-score method,
iPhos-facilitated AP treatment phosphoproteome investi-
gation demonstrates the improvement in the phosphory-
lation site localization confidence over conventional
investigation using DDA LC-MS/MS analysis.
The evaluation results using the PhosphoRS are shown
in Figure 6-b. In the results of the targeted LC-MS/MS





Protein name Sequence m/z Ratio (control
/ treatment)
ANOVA
01 IPI00977158 CTSF Cathepsin F pTRTIpYLNTLLRK 826.8552 infinity 3.8E-4
02 IPI00003384 CELSR1 Cadherin EGF LAG seven-pass G-type
receptor 1
DRDANSVITpYQLpTGGNTR 714.9915 8.57 1.7E-2
03 IPI00908866 MGAT4A Alpha-1,3-mannosyl-glycoprotein 4-beta-N-
acetylglucosaminyl-transferase A
NpYSITVpSIVMGIPTVK 632.9769 4.51 4.4E-2
04 IPI00328929 ZC3H18 Zinc finger CCCH domain-containing protein
18
RpTLSGSGSGSGSSpYSGSSpSR 701.9993 3.33 1.0E-2
05 IPI01025392 UBR7 Ubiquitin protein ligase E3 component
n-recognin 7
PLACSpYECHGSHK 542.5891 2.13 3.7E-3
06 IPI01014015 TSPAN19 Tetraspanin 19 pYCCGQHNpYpTDWIKNKNK 805.3546 1.98 2.7E-4
07 PI01009113 POLR2A cDNA FLJ53860, highly similar to DNA-
directed RNA polymerase II largest subunit
TLNpTFHpYAGVSAK 523.5813 1.65 3.1E-2
08 IPI00025468 SKIL Ski-like protein pYLGpTPEEKK 612.7616 1.54 3.6E-2
09 IPI00981378 CAMSAP2 Calmodulin regulated spectrin-associated
protein family, member 2
pTpSSVASGTEpYTGPK 812.3648 0.70 2.0E-2
10 IPI00977861 ABI3BP ABI family, member 3 (NESH) binding protein pYKNEpTLALPAESK 812.3654 0.70 2.0E-2
11 IPI00853187 LILRB3 Leukocyte immunoglobulin-like receptor
subfamily B member 3
CGpSQKGpYHHFVLMKE 970.9699 0.67 3.1E-2
12 PI00878191 DRG1 Developmentally-regulated GTP-binding
protein 1
pYLLEKIWDpYLK 822.3957 0.35 2.2E-2
13 IPI00738852 RBM44 RNA-binding protein 44 ILGEpYpTSPLpSSK 767.3362 0.34 3.2E-2
14 IPI00747652 cDNA
FLJ60027
Moderately similar to F-box only protein 25 RHGpYCpTLGETFNR 857.407 0.17 3.1E-2
15 IPI00743720 SLC25A37 Mitoferrin-1 pTVpYQLNGLAGpYFK 857.4067 0.17 3.1E-2
16 IPI00001617 SOX4 Transcription factor SOX-4 SpSAASSPAAGRSPADHRGpYApSLR 837.7143 3.2E-2 2.7E-2
17 IPI00016594 C2orf42 Uncharacterized protein C2orf42 pSFIQNRDGTpYELFK 938.9226 1.3E-2 1.8E-2
18 IPI00382739 DHX34 Probable ATP-dependent RNA helicase
DHX34
pYRINLSVLGPApTR 810.8598 0.3 2.1E-2
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analysis, 43% (83/191) phosphorylation localization of
the unique pTry peptides are calculated to be confident
under the PhosphoRS algorithm. Compared with the
results of the targeted LC-MS/MS, only 29% (55/189)
are calculated to be confident in the results of the DDA
LC-MS/MS analysis. And among these confident phos-
phorylation localization, 79.51% (66/83) of them in the
targeted LC-MS/MS analysis and 78.18% (43/55) in the
DDA LC-MS/MS analysis are reported to have probabil-
ity values of correct phosphorylation localization higher
than 0.8, a cut-off value reported to be of acceptable
false localization rate. In summary, the evaluation based
on the PhosphoRS algorithm shows that iPhos-facilitated
AP treatment phosphpoproteome investigation provides
more confident phosphorylation localization in compari-
son with conventional investigation using DDA LC-MS/
MS analysis.
Conclusions
In this study, we developed the iPhos toolkit to facilitate
and to streamline the AP-assisted phosphoproteome
investigation and evaluated the usability of iPhos through
the comprehensive pTyr phosphoproteome investigation
of the CL1-5 cells. And we also demonstrated the overall
improvement of the iPhos-facilitated phosphoproteome
investigation in the thorough phosphopeptide identifica-
tion and confident phosphorylation localization over the
pure DDA-based method. In conclusion, iPhos facilitates
Figure 5 MS/MS spectra of the peptide DEHLSTLDApYRPK. This is a demonstrating example of the iPhos-facilitated phosphopeptide
investigation. (a) From iPhos Module-1 and Module-2, the monoisotopic peak with m/z value of 812.858 was selected for targeted LC-MS/MS
analysis. (b) The MS/MS spectrum of the identified pTyr peptide DEHLSTLDApYRPK. This peptide was identified to be the fragment of the protein
“Similar to ankyrin repeat domain 20A, isoform CRA_a” (m/z 812.86, 2+) with a Mascot score of 39.
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the pipeline of AP-based comprehensive phosphopeptide
investigation, allowing for rapid production of vital biolo-
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